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1002-44A Col laborative Angiogrephlc  Potency Trial of  
Recombinant Staphylokinase (CAPTORS II) 
Paul W. Armstrona. Jeffrey Burton, Peter G. Molhoek, Amadeo Betdu, Michal Tendera, 
Chdstoph Bode, Frlts Bar, Jennifer Adgey, Alex Vahanian, Frans Van de Weft, for the 
CAPTORS II Investigators, University of Alberta, Edmonton, Alberta, Canada. 
Our pdmary objective was to compare bolus dose(s) of PEGylated staphylokinase (PEG- 
Sak) to rt-PA as assessed by culprit infarct vessel patancy at 60 minutes. Additional 
objectives were to examine the safety profile of PEG-Sak. net clinical benefit and con- 
ventional 30-day clinical sequelae of acute myocardial infarction. We used a randomized, 
parallel-group, sequential design clinical trial comparing a novel potent highly fibrin spe- 
cific fibdnolytic agent, single bolus PEG-Sak with conventional frent-loaded recombinant 
tissue plasminogen activator (rt.PA). Both treatment arms employed unfractionatad hep- 
arin according to ACC/AHA guidelines. The table below shows 60 minute TIMI 3. com- 
bined TIMI 2/3 patancy (mean with 95% confidence intervals) and median frame counts 
for TIMI 2/3 patients for those randomized to PEG-Sak in a single-bolus, weight- 
adjusted, dose-finding strategy ranging from 0.01 mg/kg to 0.15 mg/kg as compared with 
conventional weight-edjustad, front-loaded rt-PA. Patients studied were those presenting 
with acute ST elevation myocardial infarction within six hours of symptom onset. Anglo- 
graphic potency was assessed by a blinded core angiographic laboratory system. 
Conclusion: These data support pharmacologic efficacy for PEGylated staphylokinase as 
compared with rt-PA across a wide range of doses with some attenuation of efficacy at 
0.01 mg/kg. 
PEG-Sakdosemg/kg n=sample T1M]3 TIMI2/3 Frame count from ICH-#pts 
size (95% C.I.) (95% C.I.) T1MI 2/3 (n=pts) 
• 01 19 37 (16-62) 53 (29-76) 22 (t0) 
.01875 96 33 (24-44) 63 (52-72) 26 (60) 1 
.025 I10 35 (26-44) 62 (52-71) 29 (68) 
.0375 103 34 (25-44) 66 (56-75) 28 (68) 1 
.05 23 43 (23-66) 74 (52-90) 29 (17) 2 
rt-PA 112 42 (33-52) 70 (60-78) 28 (78) 1 
1002-45 Intravenous Adenosine Diphoaphate P2T Platelet 
Receptor Antagonism as an Adjunct  to Fibrinolysis for  
Acute Myocardial Infarction 
Adam B. Greenbaum. E. M. Ohman, Michael S. Gibson, Steven L. Borzak, Michel 
LeMay, Mei Lu, Amanda L. Stebbins, Hakan Emanuelsson, W. D. Weaver, Henry Ford 
Heart and Vascular Institute, Detroit, Michigan. 
Background: Oral adenosine diphoshate (ADP) platelet receptor antagonists have 
shown benefit during acute coronary syndromes. Our aim was to investigate a novel 
intravenous ADPp2 T platelet receptor antagonist during fibrinolysis for acute myocardial 
infarction (AMI). 
Methods: Patients presenting within 6 hours of AMI were randomized to receive 35-, 
140-, or 280 pg/min AR-C69931MX along with 50 mg t-PA administered over 60 minutes, 
280 ug/min AR-C69931MX alone, or standard dose t-PA in the Safety, Tolerability and 
Effect on Patancy in Acute Myocardial Infarction (STEP-AMI) tnal. All patients underwent 
60-minute angiography and rescue intervention if necessary. Patients were followed 
through 30 days. The primary endpoint was thrombolysis in myocardial infarction (TIMI) 
grade flow at 60 minutes by independent core laboratory analysis. 
Results: The trial was stopped after 101 of 240 planned patients were enrolled. Of 81 
evaluable films, complete repeftusion was achieved in 57% of patients receiving combi- 
nation therapy compared with 50% with t-PA alone, p=NS (see table). Major adverse clin- 
ical events (MACE) and bleeding complications were comparable between combination 
therapy and standard dose t-PA groups (20% and 17% non-CABG related TIMI major 
bleeding rates, respectively). No intracranial hemorrhage was observed. 
Conclusion: Early experience with intravenous ADPp2 T platelet receptor antagonism 
suggests feasibility and possible improvements in repeftusion during fibdnolysis for AMI. 
t-PA t-PA + P2T (35 t-PA + P2T( 140 t-PA + P2T(280 P2T alone (280 
alone ~g/min) I.tg/min) IJg/min) pg/min) 
TIMI grade 3 flow 3 10 (53%) 11 (61%) 12 (55%) 3 (19%) 
(50%) 
TIMI frame count 58±46 53±32 49±30 54±42 78±31 
ST-segment 1 4 (24%) 5 (28%) 5 (33%) 2 (13%) 
recovery>70% (14%) 
30-day MACE 0 (0%) 4 (17%) 3 (13%) 3 (12%) 0 (0%) 
Non-CABG TtMI 1 3 (18%) 8 (33%) 3 (13%) 2 (11%) 
major bleed ( t 7%) 
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1002-46 Aging of Intrecoronary Thrombus Due to Delayed Time- 
to-Reperfualon Increases Ischemic and Angiographic 
Complications in Acute Myocardial Infarction 
Satvendra Girl. Michael Gibson, Andrew C. Eisenhauer, Richard E. Kuntz, Campbell 
Rogers, Sabina Murphy, Joseph Mitchel, Elliott M. Antman, Daniel I. Simon, Brigham & 
Women's Hospital Boston, Massachusetts, Harvard Clinical Research Institute, Boston, 
Massachusetts. 
BACKGROUND: Progressive cross-linking of fibrin produces temporal change in Throm- 
bus (7") composition making an aged T firmer, lysis-resistant and more likely to result in 
distal flow and ischemic complication than fresh T We hypothesized that in myocardial 
infamtion(AMI), both delay in "time to reperfusion" and T are associated with flow and 
ischemic complications with an interaction between the two. 
METHODS: We analyzed AMI pts from TIMI 4, 10, & 14 trials (n=2321) who presented 
<12 hr of symptom and received fibrinolysis. Total ischemia time (symptom onset to nee- 
die) was delayed if > 4 hr. Twas assessed with quantitative angiography. 
RESULTS: Tpts were more likely to have TIMI flow <3 (72% vs 26%), 90-min infarct ves- 
sel occlusion (54% vs 3%), prolonged TIMI frame count (CTFC: 42_+.27 vs 35+_21 ),pulmo- 
nary edema (4% vs 2%), pump failure (6% vs 3%), severe ischemia (55% vs 19%), 
rescue PTCA (41% vs 1%), and death (6% vs 3%) [all p<0.01]. 
Pts with delayed presentation were more likely to have vessel occlusion at 90-rain (25% 
vs 18%, p<0.001), TIMI flow <3 (44% vs 40%, p=0.07), pump failure (2% vs 1%, p=0.05), 
and death (6% vs 3%, p=0.007). In multivariate analysis, T and "T & total ischemia time 
interaction" were predictive of angiographic antegrade flow variables and >=70% ST seg- 
ment resolution. (TABLE) 
CONCLUSION: Interaction is such that T results in more flow and ischemic complica- 
tions with delayed peftusion time. Rescue PTCA in the setting of Tand delayed presen- 
tation may require alternative strategy to reduce Tburden. 
Multivariable predictors Odds 95% C.I. pvalue 
Ratio 
Predictors of >=70% ST segment resolution 
Absence of coronary thrombus 0.40 
Thrombus & total-ischemia-time Interaction 0.57 
Predictors of 90-minute TIMI 3 antegrade flow 
Absence of coronary thrombus 0.17 
Thrombus & total-ischemia-fime Interaction 0.45 
Predictors of 90 minute Corrected TIMI Frame Count 
Presence of coronary thrombus 
Thrembus & total-ischemia-time Interaction 
0.26 - 0.62 0.0001 
0.38 - 0.86 0.007 
0.14 - 0.22 0.0001 
0.29 - 0.72 0.001 
34.51 31.68-37.34 0.0001 
13.08 7.93- 18.23 0.0001 
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1003-31 Magnesium Reduces Free Radicals Generated by Direct 
Current Shocks and Prevents Left Ventricuiar 
Dysfunction in an In Vivo Swine Model 
Yi Zhano. Loyd R, Davies, Sean M. Martin, Garry R. Buettner, Richard E. Kerber, The 
University of Iowa, Iowa Ci~ Iowa. 
Backoround: Oxygen free radicals are generated by myocardial ischemia-repeftusion 
sequences or by direct current countershocks for the termination of ventdcular fibrillation. 
We have previously shown that magnesium reduces free radicals in a coronary occlu- 
sion-repeftusion model. The purpose of this study was to determine if magnesium 
reduces free radicals generated by direct current countershocks. 
Methods: Eight swine weighing 18 to 27 kg underwent a midline stamotomy. Using elec- 
tron paramagnetic resonance, we continuously monitored the coronary sinus concentra- 
tion of ascorbate free radical (Asc'-), a measure of free radical generation (total oxidative 
flux). A 30 Joule epicardial shock using a truncated exponential biphasic waveform (5/5 
msec) was administered to generate free radicals. Each animal received 2 shocks. No- 
magnesium shocks were given while the animals were receiving intravenous aline infu- 
sion. Magnesium shocks were given while the animals received magnesium (80 rag/rain) 
beginning 10 rain before the shock and continuing to 15 rain after the shock. Left ventric- 
ular fractional area shortening was determined by 2-dimensional (2-D) echocardio- 
graphy. 
Results: Magnesium pre-treatment significantly (p<O.05) reduced Asc" concentration 
after biphasic shocks. The peak increase in Asc °" concentration was 18% (no-magne- 
sium shocks) vs. 5% (magnesium shocks); the total radical flux after shocks was reduced 
by 72% by magnesium pre-treatment. Using 2-D echo, the fractional area shortening at 
baseline (before shocks) was 69 _+ SE 3%; after no-magnesium shocks, the percent frac- 
tional area shortening fell to 41 + 3% (p<0.001), whereas shocks given after pretreatment 
with magnesium resulted in fractional area shortening of 61 +_ 4% (p=NS vs. baseline). 
Conclusions: Magnesium pre-treatment reduces oxygen free radicals generated by 
biphasic shocks and prevents left ventricular dysfunction. Magnesium may be cardiopro- 
tactive dudng defibrillation. 
